Business
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN), a biotechnology company
About this update from Promis Neurosciences Inc.
[{"type":"text","content":"TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), is pleased to announce the Annual Meeting of Shareholders was held by virtual web-cast meeting, on Thursday, June 29, 2023 at 9:30 a.m. (Eastern time). With 51.23% of common shares represented at the Meeting, and 93.51% series 1 preferred shares represented at the meeting, shareholders approved all resolutions by a highly favorable majority. In compliance with securities regulations and Toronto Stock Exchange (“TSX”) requirements, the Corporation has posted the results of the voting below. All Resolutions Passed At the Meeting, holders of common shares (“Common Shareholders”) were asked to consider and vote on the following: 1. ELECTION OF DIRECTORS: Common Shareholders re-elected seven directors of the Corporation. Dr. Gail Farfel, CEO of ProMIS since September 2022, was also elected as a director: DirectorVotes ForVotes AgainstAbstentions% For% AgainstEugene Williams3,320,369147,92112,87295.73%4.26%Neil Cashman, M.D.3,470,2658,6112,28699.75%0.24%Gail Farfel, Ph.D.3,376,107103,3021,75397.03%2.96%Patrick D. Kirwin3,314,138154,64012,38495.54%4.45%Joshua Mandel-Brehm3,316,160112,63652,36696.71%3.28%Maggie Shafmaster, Ph.D., JD3,292,796103,92484,44296.94%3.05%Neil K. Warma3,266,932164,17450,05695.21%4.78%William Wyman3,048,981382,12450,05788.86%11.13% Broker non-votes: 914,356 2. APPOINTMENT OF AUDITOR: Common Shareholders voted in favor of the ordinary resolution to appoint Baker Tilly US, LLP as auditor of the Corporation for the ensuing year and to authorize the directors to fix the auditor’s remuneration. Appointment of AuditorVotes ForVotes AgainstAbstentions% For% AgainstAppointment of Baker Tilly US, LLP4,294,82499,5911,10397.73%2.26% At the Meeting, Common Shareholders and the holders of series 1 preferred shares (“Series 1 Preferred Shareholders”) were asked to consider the following: 3. Continuance Resolution: Common Shareholders and Series 1 Preferred Shareholders, voting together, voted in favor of a special resolution authorizing th...